- Home
- STOK
as of 12-08-2025 3:59pm EST
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | BEDFORD |
| Market Cap: | 1.7B | IPO Year: | 2019 |
| Target Price: | $31.00 | AVG Volume (30 days): | 880.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.68 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.35 - $38.69 | Next Earning Date: | 11-04-2025 |
| Revenue: | $205,632,000 | Revenue Growth: | 1128.17% |
| Revenue Growth (this year): | 430.24% | Revenue Growth (next year): | -82.00% |
AI-Powered STOK Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Stoke Therapeutics Inc. (STOK)
CHIEF MEDICAL OFFICER
Avg Cost/Share
$30.59
Shares
2,014
Total Value
$61,725.11
Owned After
15,156
Director
Avg Cost/Share
$30.59
Shares
1,070
Total Value
$32,793.47
Owned After
51,956
GENERAL COUNSEL & CORP SEC
Avg Cost/Share
$30.59
Shares
2,292
Total Value
$70,245.22
Owned After
21,006
CHIEF MEDICAL OFFICER
Avg Cost/Share
$29.85
Shares
2,006
Total Value
$59,743.26
Owned After
15,156
Director
Avg Cost/Share
$29.85
Shares
1,066
Total Value
$31,747.95
Owned After
51,956
GENERAL COUNSEL & CORP SEC
Avg Cost/Share
$29.85
Shares
2,284
Total Value
$68,022.96
Owned After
21,006
Director
Avg Cost/Share
$29.72
Shares
40,472
Total Value
$1,202,718.57
Owned After
323,774
SEC Form 4
Director
Avg Cost/Share
$26.98
Shares
40,472
Total Value
$1,092,058.26
Owned After
323,774
CHIEF MEDICAL OFFICER
Avg Cost/Share
$27.03
Shares
5,931
Total Value
$152,565.55
Owned After
15,156
Director
Avg Cost/Share
$30.00
Shares
25,000
Total Value
$750,000.00
Owned After
51,956
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Ticho Barry | STOK | CHIEF MEDICAL OFFICER | Dec 3, 2025 | Sell | $30.59 | 2,014 | $61,725.11 | 15,156 | |
| Kaye Edward M. MD | STOK | Director | Dec 3, 2025 | Sell | $30.59 | 1,070 | $32,793.47 | 51,956 | |
| Allan Jonathan | STOK | GENERAL COUNSEL & CORP SEC | Dec 3, 2025 | Sell | $30.59 | 2,292 | $70,245.22 | 21,006 | |
| Ticho Barry | STOK | CHIEF MEDICAL OFFICER | Dec 2, 2025 | Sell | $29.85 | 2,006 | $59,743.26 | 15,156 | |
| Kaye Edward M. MD | STOK | Director | Dec 2, 2025 | Sell | $29.85 | 1,066 | $31,747.95 | 51,956 | |
| Allan Jonathan | STOK | GENERAL COUNSEL & CORP SEC | Dec 2, 2025 | Sell | $29.85 | 2,284 | $68,022.96 | 21,006 | |
| Krainer Adrian R. | STOK | Director | Nov 24, 2025 | Sell | $29.72 | 40,472 | $1,202,718.57 | 323,774 | |
| Krainer Adrian R. | STOK | Director | Nov 14, 2025 | Sell | $26.98 | 40,472 | $1,092,058.26 | 323,774 | |
| Ticho Barry | STOK | CHIEF MEDICAL OFFICER | Nov 3, 2025 | Sell | $27.03 | 5,931 | $152,565.55 | 15,156 | |
| Kaye Edward M. MD | STOK | Director | Oct 8, 2025 | Sell | $30.00 | 25,000 | $750,000.00 | 51,956 |
Compare STOK vs Leading Stocks
See how STOK stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "STOK Stoke Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.